Gastrointestinal Bleeding Prevention in Anticoagulation Therapy
Patient Selection for PPI Therapy
- Patients at increased risk of gastrointestinal bleeding, including those with a history of prior gastrointestinal bleeding, advanced age (≥65-75 years), concomitant use of multiple antithrombotic agents, concurrent use of steroids or NSAIDs, severe medical comorbidities, or Helicobacter pylori infection, should be considered for PPI therapy, as recommended by the European Society of Cardiology and the American Heart Association 1, 2, 3, 4
- The European Society of Cardiology recommends using a proton pump inhibitor in patients on combined antithrombotic therapy who have increased risk of gastrointestinal bleeding, with risk factors including age >65 years, history of GI bleeding or peptic ulcer disease, concurrent use of multiple antithrombotic agents, chronic steroid or NSAID use, and high alcohol consumption 1
PPI Therapy Duration and Monitoring
- PPI therapy should continue for as long as the patient remains on anticoagulation therapy if they have high bleeding risk, as recommended by the European Society of Cardiology 1
- For patients with lower risk, consider periodic reassessment of the need for continued PPI therapy, according to Gastroenterology 4
PPI Interactions and Adverse Effects
- Omeprazole and esomeprazole may reduce clopidogrel's effectiveness through CYP2C19 inhibition, and alternative PPIs (pantoprazole, lansoprazole) should be considered when co-prescribing with clopidogrel, as recommended by the European Society of Cardiology 1
- PPIs may have potential adverse effects, including increased risk of C. difficile infection, bone fractures, vitamin B12 deficiency, and acute tubulointerstitial nephritis 1
Antithrombotic Therapy Management
- The European Heart Journal recommends limiting the duration of dual antiplatelet therapy (DAPT) to the minimum necessary period based on indication 1
- The Gut journal suggests continuing aspirin therapy even during acute GI bleeding when used for secondary prevention, with a prospective RCT showing lower all-cause mortality (1.3% vs 12.9%) in patients continuing low-dose aspirin after endoscopically controlled upper GI bleeding 5
- The European Heart Journal suggests using direct oral anticoagulant (DOAC) preferably over vitamin K antagonist for patients requiring both anticoagulation and antiplatelet therapy after PCI, with a limit on triple therapy (DOAC + aspirin + clopidogrel) to ≤1 week 1, 6
Procedure-Related Antithrombotic Therapy Management
- The Gut journal recommends continuing aspirin for all low-risk endoscopic procedures, continuing P2Y12 inhibitors for low-risk procedures, and continuing warfarin therapy ensuring INR doesn't exceed therapeutic range 5
- The Gut journal suggests discontinuing P2Y12 inhibitors 7 days before procedure in low thrombotic risk patients, discontinuing warfarin for 5 days before procedure and ensuring INR <1.5, and taking the last dose of DOACs at least 48 hours before procedure (72 hours for dabigatran if CrCl 30-50 mL/min) 7, 5
Antithrombotic Therapy Resumption after Bleeding
- The European Heart Journal recommends resuming anticoagulation preferably within 3 days with heparin bridging for high thrombotic risk patients, and after 7 days of interruption for low thrombotic risk patients 5
- The European Heart Journal suggests considering reduced doses of rivaroxaban (15mg daily instead of 20mg) and dabigatran (110mg twice daily instead of 150mg twice daily) when bleeding risk is high 1
- The Gut journal notes that development of stent thrombosis carries approximately 40% risk of MI and death, and that delaying anticoagulation resumption beyond 7 days in high thrombotic risk patients significantly increases mortality and thrombotic events 7, 5